Market closedADR
Cellectis/$CLLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Ticker
$CLLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
219
Website
Cellectis Metrics
BasicAdvanced
$111M
-
-$0.41
3.38
-
Price and volume
Market cap
$111M
Beta
3.38
52-week high
$3.38
52-week low
$1.10
Average daily volume
604K
Financial strength
Current ratio
1.727
Quick ratio
1.693
Long term debt to equity
26.135
Total debt to equity
44.847
Interest coverage (TTM)
-11.22%
Management effectiveness
Return on assets (TTM)
-10.37%
Return on equity (TTM)
-34.08%
Valuation
Price to revenue (TTM)
2.668
Price to book
1.03
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
6.859
Growth
Revenue change (TTM)
435.37%
Earnings per share change (TTM)
-76.87%
3-year revenue growth (CAGR)
8.44%
3-year earnings per share growth (CAGR)
-45.61%
What the Analysts think about Cellectis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cellectis stock.
Cellectis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cellectis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cellectis News
AllArticlesVideos
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
GlobeNewsWire·1 month ago
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cellectis stock?
Cellectis (CLLS) has a market cap of $111M as of April 21, 2025.
What is the P/E ratio for Cellectis stock?
The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of April 21, 2025.
Does Cellectis stock pay dividends?
No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of April 21, 2025.
When is the next Cellectis dividend payment date?
Cellectis (CLLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis?
Cellectis (CLLS) has a beta rating of 3.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.